FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Accord Biopharma Imuldosa Recall

IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single dose via…

ACCORD BIOPHARMA INC · Raleigh, NC

Risk level
Class II
Reported by FDA
Jul 8, 2026
Recall ID
D-0653-2026
Check your lot numberHow we source this data

Summary

Accord Biopharma recalled Imuldosa starting Jun 10, 2026. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0653-2026 on Jul 8, 2026. Reason: Lack of assurance of Sterility:. Status: Ongoing.

Why it was recalled

Lack of assurance of Sterility:

Product description

IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single dose vial, Manufactured by Accord BioPharma Inc., 8041 Arco corporate Drive, Suite 200, Raleigh, NC 27617, USA, Manufactured at: Catalent Indiana, LLC, 1300 S. Patterson Drive, Bloomington, IN 47403, USA, NDC 69448-019-26.

Lot numbers, UPCs & expiration codes

Lot # 004L24A, Exp Date: 02/19/2027.

Where it was sold

US Nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0653-2026
Classification
Class II
Status
Ongoing
Recall initiated
Jun 10, 2026
FDA report date
Jul 8, 2026
Quantity
326 vials
Recall type
Voluntary: Firm initiated
Recalling firm
ACCORD BIOPHARMA INC

Original FDA data

Every field from FDA enforcement report D-0653-2026, exactly as published.

Show all FDA fields
City
Raleigh
State
NC
Status
Ongoing
Country
United States
Event ID
99216
Address
8041 Arco Corporate Dr Ste 200
Code information
Lot # 004L24A, Exp Date: 02/19/2027.
Postal code
27617-2091
Report date
Jul 8, 2026
Product type
Drugs
Recall number
D-0653-2026
Classification
Class II
Recalling firm
ACCORD BIOPHARMA INC
Product quantity
326 vials
Reason for recall
Lack of assurance of Sterility:
Voluntary / mandated
Voluntary: Firm initiated
Product description
IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single dose vial, Manufactured by Accord BioPharma Inc., 8041 Arco corporate Drive, Suite 200, Raleigh, NC 27617, USA, Manufactured at: Catalent Indiana, LLC, 1300 S. Patterson Drive, Bloomington, IN 47403, USA, NDC 69448-019-26.
Distribution pattern
US Nationwide.
Recall initiation date
Jun 10, 2026
Initial firm notification
Letter
Center classification date
Jun 29, 2026

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0653-2026, published Jul 8, 2026. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls